SecBot SecBot

COGT

Cogent Biosciences, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001622229 Biotech & Drug Discovery
$27.44 −1.12 (−3.92%)
Nov 16 4:00 PM ET · prev $28.56
Market cap
$5.1B
Mid cap
Consensus
Buy
89% Buy or better · 18 analysts
Median target
$55.00
+100% · range $45.00–61.00
1 year
−18.7%
from $33.75 · Nov 17
30 days
−8.6%
from $30.01
52-week range
$27.44–42.84
at the low
Avg volume 20D
2.05M
shares / day
Short interest
17.42M
≈10.0% of shares · −11.4%
Days to cover
8.7
at average volume
Insider net
−$244.3M
0 buyers · 2 sellers · 12 mo
New fund stakes
3
Q3 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next FDA decision date, Nov 30, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $244.3M.

  • InstitutionsBULLISH

    Q3 2026: 38 added (3 new), 17 trimmed or exited. Largest new: Loomis Sayles & L P $35.7M, Hrt Financial $10.1M.

  • AnalystsBULLISH

    16 of 18 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −11.4% to 17.42M shares. 8.7 days to cover, ≈10.0% of shares.

  • TrendRANGE

    12% below its 50-day average. New closing low $27.44 on Nov 16.

Who's buying

13F· Q3 2026
3
new positions
0
exits
$45.8M
in new stakes · top 2 shown
FundMoveSharesValue
FRANKLIN TEMPLETON INCDOUBLED1,938,543$61.0M
UBS Group AGADD1,678,094$53.7M
LOOMIS SAYLES & CO L PNEW1,115,760$35.7M
Nuveen, LLCADD875,578$28.0M
RENAISSANCE TECHNOLOGIES LLCTRIM708,668$22.7M
BNP PARIBAS FINANCIAL MARKETSADD657,447$21.1M
Aberdeen Group plcADD588,628$18.8M
MORGAN STANLEYTRIM511,231$16.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 89% rate it Buy or better
Strong Buy8Buy8Hold2Sell0Strong Sell0
12-month targets · 11 analysts

Price is below the lowest target. Median implies +100%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Sep 16, 2026Wedbush
REITERATE
REITERATEOutperform
Sep 15, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 17, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Aug 12, 2026Guggenheim
MAINTAIN
MAINTAINBuy
May 29, 2026Wedbush
REITERATE
REITERATEOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$244.3M
sold · 2 insiders
DateInsiderTypeValue
Oct 1, 2026
Ferrante Karen Jean
Director
Oct 1, 2026
AWARD759 sh
Aug 27, 2026
Morris Arlene
Director
Aug 27, 2026
SELL$118.7K
Aug 27, 2026
Morris Arlene
Director
Aug 27, 2026
EXERCISE$9.0K
Aug 27, 2026
Morris Arlene
Director
Aug 27, 2026
EXERCISE$236.5K
Aug 27, 2026
Morris Arlene
Director
Aug 27, 2026
SELL$1.6M
Jul 1, 2026
Ferrante Karen Jean
Director
Jul 1, 2026
AWARD627 sh
Jun 9, 2026
Ros Matthew
Director
Jun 9, 2026
AWARD17,901 sh
Jun 9, 2026
Harwin Peter Evan
Director
Jun 9, 2026
AWARD17,901 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY-$2.33-$2.53–-$2.02-5.4%$5.2M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
17,416,118
shares short
-11.4%
vs prior settlement
8.7
days to cover
≈10.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 Earnings calendar
COGT Q3 2026 Earnings Scheduled · 2026-11-10
Nov 9, 2026 SEC
Seven institutional investors added $16.3M in net new COGT positions during Q3 2026, while two trimmed $3.5M. The…
INST-CLUSTER · Impact 3/10
Nov 5, 2026 SEC
Cogent Biosciences reported Q3 2026 net loss of $111.4M, wider than the $80.9M loss in Q3 2025, driven by increased…
8-K · Impact 4/10
Nov 5, 2026 SEC
Cogent Biosciences reported Q3 2026 net loss of $111.4M, wider than the $80.9M loss in Q3 2025, driven by increased…
PRESS-RELEASE · Impact 5/10
Oct 1, 2026 Insider
Ferrante Karen Jean was granted 759 shares
Director
Sep 30, 2026 Inst.
FRANKLIN TEMPLETON INC · DOUBLED
1,938,543 shares ($61.0M)
Sep 30, 2026 Inst.
UBS Group AG · ADD
1,678,094 shares ($53.7M)
Aug 27, 2026 Insider
Morris Arlene sold 3,161 shares
Director @ $37.54 ($118.7K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent

SecBot reports

7 filings · 6 press releases · 1 bullish · 0 bearish · 6 neutral
All COGT filing & press-release reports (13)